ZEISS Meditec in Dublin, California

USA Management

 

James V. Mazzo

James V. Mazzo

James V. Mazzo is Global President for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers. He also heads the company’s U.S. Sales and Service Center.

Mazzo is one of the ophthalmic industry’s most respected business leaders, with more than 36 years of experience, including 22 years leading Allergan’s North American and European eye care organizations; seven years as Chairman, President and CEO of Advanced Medical Optics (AMO); four years as EVP of Abbott’s global ophthalmology business; and three years as Executive Chair and CEO of AcuFocus. In addition, Mazzo is Chairman of Neurotech; on the board of OCTANe, RPS and Iantech; and Executive Committee Board Member with MDMA.

His accomplishments and contributions to the healthcare industry and business and educational communities include serving as Board Chairman for AdvaMed; on the University of California at Irvine foundation; as trustee Chapman University; and as past trustee for University of San Diego. Mazzo is on the ASCRS Governing Board, the AAO Foundation Advisory Board and the WOC Advisory Board.

Roberto Deger

Roberto Deger

Roberto Deger is Chief Financial Officer and a Member of the Board of Directors of the company’s US subsidiary, Carl Zeiss Meditec Inc, as well as Head of Finance for Carl Zeiss Meditec’s Global Strategic Business Unit Ophthalmic Devices.

Deger joined ZEISS in 2008 as Senior Financial Analyst for the Semiconductor Manufacturing Technology (SMT) business group before assuming the role of Senior Director of the SMT’s Finance, Controlling and Risk Management Group in 2009.

Deger was appointed CFO and Member of the Board of Directors for SMT’s Strategic Business Unit (SBU) Semiconductor Metrology Systems (SMS), the Photomask division of SMT, in 2012. In this role, he was also responsible for the Order Fulfillment process of the SBU SMS. Prior to joining ZEISS, Deger worked as a Financial Analyst at Bayer AG, where he later became Director of Finance, Controlling and Supply Chain at LANXESS, the chemical business of the BAYER Group.

Steven Schallhorn, MD

Steven C. Schallhorn, MD

Steven Schallhorn, MD is Chief Medical Officer for Carl Zeiss Meditec’s Global Strategic Business Unit Ophthalmic Devices. Dr. Schallhorn is a board certified, licensed ophthalmologist in private practice in San Diego, California, a Clinical Professor of Ophthalmology at the University of California, San Francisco and the Chief Medical Director for Optical Express.

After graduating from Colorado State University, Captain Schallhorn served in the US Navy as an F-14 aviator and a Navy Fighter Weapons School instructor (TOPGUN). He completed his medical degree at the Uniformed Services University of the Health Sciences, ophthalmology residency at the Naval Medical Center San Diego, and cornea fellowship at the Doheny Eye Institute, University of Southern California. He founded the Department of Defense refractive surgery program and directed the Naval Medical Center San Diego.

Dr. Schallhorn has served on the Executive Committee for the American Academy of Ophthalmology International Society of Refractive Surgeons, as Chairman of the AAO ISRS Program Committee, as Chairman of the AAO Refractive Ophthalmic Technology Assessment Committee, and as Editor for the AAO ONE Program. Dr. Schallhorn has been a visiting professor of medicine at Harvard, USC, UCSF and Baylor. Dr. Schallhorn has received the ASCRS Binkhorst award, the AAO Lans award and the ISRS 2016 Casebeer Award for outstanding contributions to refractive surgery.

Andrew Chang

Andrew Chang

Andrew Chang is Head of Global Sales for Carl Zeiss Meditec’s Strategic Business Unit Ophthalmic Devices, which includes Ophthalmic Diagnostics, Surgical Ophthalmology and Refractive Lasers.

Prior to his joining ZEISS, Chang was General Manager and Senior Vice President for Bausch + Lomb Surgical where he led the sales, marketing, operations and business development for the US. Previously at Optimedica Corporation / Abbott Medical Optics, Inc., Chang led the marketing and launch of new laser systems and new indications globally. At ISTA Pharmaceutical / Bausch + Lomb, Chang held various marketing, sales and product development roles and led the market introductions of ophthalmic pharmaceuticals.